Redeye comments on Fluoguide’s Q1 2024 report, following its recent announcement of a collaboration with Intuitive Surgical in head and neck cancer RAS. We judge the company is making solid progress in executing its new strategy, even though current news flow is not as dense as in 2023. We do some housekeeping in our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/